Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) can progress to cirrhosis, hepatocellular carcinoma (HCC), death, or liver transplantation. NASH has also been associated with impaired health-related quality of life and poses a significant economic burden. Due to the negative clinical and patient-reported outcomes and economic burden of NAFLD, it is necessary to review this disease through the lens of value-based care, in which value is proportional to clinical and quality outcomes and inversely proportional to the costs of delivering these outcomes. I review the components of outcomes measured for patients with NAFLD and NASH and relate them to the value proposition, with the aim to deliver optimal patient-centered care. (Hepatology 2018;68:2405-2412).
O utcomes frequently measured in studies of patients with chronic diseases such as nonalcoholic fatty liver disease (NAFLD) include morbidity and mortality.
(1-3) Since these outcomes are difficult to measure in clinical trials, investigators rely on histologic, radiologic or other biomakers as surrogates of clinical outcomes.
(1-6) However, assessments of the burden of NAFLD that are limited only to these clinical outcomes do not fully capture the impact of this disease on patients and society. (4) (5) (6) A comprehensive understanding of the burden of NAFLD requires information not only on clinical outcomes but also on patient-reported outcomes (PROs) and economic outcomes. (4) (5) (6) A combination of clinical and quality outcomes, in the context of the cost of care, is required to assess the full impact of NAFLD in the context of the value proposition. Although much has been written about the clinical effects of NAFLD, little has been written about its PROs and economic burden. I review these outcomes and discuss how their analysis can increase our understanding of the burden of NAFLD and ways to provide value-based and patient-centric care.
(2)
Clinical Burden of NAFLD
The global prevalence of NAFLD in adults is estimated to be approximately 25%. (7) The prevalence of NAFLD increases with increasing body mass index. One study reported that 67% of overweight and 94% of obese individuals have NAFLD. (8) Although NAFLD is highly prevalent in the general population, its progressive subtype of nonalcoholic steatohepatitis (NASH) is more clinically relevant.
(1-9) In the United States, an estimated 1.5%-6.45% of the general population has NASH. (9) Histologic assessments of biopsies from living liver transplant donors who are considered healthy confirmed these data, providing additional support for the prevalence of NASH in the general population. The prevalence of NASH in healthy liver donors from Europe has been reported to range from 3% to 16%; the prevalence in liver donors from the United States ranges from 6% to 15%.
(1- 15) The high prevalence of NAFLD is only one part of its clinical burden, but it is also important to consider its long-term effects. Longitudinal studies of NAFLD have reported an increase in all-cause mortality, cardiovascular mortality, and liver-related mortality (13) -primarily in patients with NASH.
(1-13) Stage of hepatic fibrosis appears to be the most important determinant of mortality in patients with NAFLD. (14) (15) (16) Risk of death appears to increase with increasing stage of fibrosis: stage 1, mortality rate ratios (MRRs) = 1. 58 (14) In addition to death, other important outcomes to measure are the development of hepatocellular carcinoma (HCC) and listing for liver transplantation. A recent study of 26,000 individuals (34% with NAFLD) followed for 164,671 person-years (median, 7.5 years) found that patients with NAFLD had a higher incidence of cancers than individuals without NAFLD (782.9 versus 592.8 per 100,000 person-years; hazard ratio [HR], 1.32; 95% CI, 1.17-1.49; P < 0.001). After the authors controlled for demographic variables, NAFLD (with and without fibrosis) was associated with HCC (HR, 16.73; 95% CI, 2.09-133.85; P = 0.008). (12) A study from England reported that NAFLD is the leading cause of HCC-related liver transplantation. (17) An analysis of the National Cancer Institute, Surveillance, Epidemiology, and End Results Program database concluded that NAFLD is not only among the top causes of HCC in the United States but also independently associated with mortality in patients with HCC. (18) In addition to death and HCC, placement on the waitlist for liver transplantation is an important outcome. NASH has become the fastest-growing and the second or third leading indication for liver transplantation in the United States. (19, 20) The clinical burden of NAFLD and NASH has therefore become quite worrisome. In fact, it is estimated that the future burden of NASH will be fueled not only by its high prevalence in children (21, 22) but also by the increasing rates of obesity and type 2 diabetes worldwide. A recent modeling study projected the incidence of NAFLD using historical and projected changes in adult prevalence of obesity and type 2 diabetes mellitus. The model predicted that the prevalence of NAFLD would increase 21%, from 83.1 million in 2015 to 100.9 million in 2030; and the prevalence of NASH would increase 63%, from 16.52 million in 2015 to 27.00 million cases in 2030. This means that the prevalence of NAFLD in the adult population will be 33.5% in 2030 (27% of the NAFLD cases will be NASH), and the median age of the NAFLD population will increase by 5 years, to 55 years. Liver-related adverse outcomes will also increase by 2030, such that the incidence of decompensated cirrhosis will increase 168%, to 105,430 new cases; whereas the incidence of HCC will increase 137%, to 12,240 cases; and liver deaths will increase 178%, to an estimated 78,300 annually, leading to a projected 800,000 excess liver deaths. (23) The most difficult conundrum regarding NASH is related not only to its growing clinical burden but also to the lack of an effective treatment regimen. There are no effective treatments for NASH beyond lifestyle modification with diet and exercise. However, clinical trials are in progress for agents designed to stop or reverse progression of NASH-related fibrosis, by targeting pathways believed to be required for disease progression. (24) 
PROs
An important aspect of delivering patient-centered care to patients with NAFLD is to assess not only clinical outcomes but also quality outcomes-especially PROs. In fact, patient-centered care is built on the premise of including patients' perspective and input about their disease and its management. In this context, PROs are the surrogates of patients' experiences. PROs are determined from patient-completed self-reports on health and well-being, without modification by anyone else. (25) PROs therefore capture information on broad concepts such as health-related quality of life (HRQL), fatigue, work productivity, functional status, satisfaction, and compliance. (26) In general, PROs are measured using validated tools or questionnaires to assess the specific construct affected by the disease process or its treatment. (27) Although many different PROs are analyzed, HRQL is one of the most important. HRQL covers multidimensional constructs related to physical, mental, and social health, from patients' own perspectives. (25, 28, 29) In general, HRQL and other PROs are assessed using validated instruments or questionnaires that are divided into general measures (generic instruments) and disease-specific instruments.
(2,6,30-32) Instruments most commonly used to measure PROs in patients with liver disease include the Short Form-36 (SF-36), the Chronic Liver Disease Questionnaire (CLDQ) and its different versions, the EQ-5D, the Sickness Impact Profile, the Functional Assessment of Chronic Illness Therapy-Fatigue instrument, and the Work Productivity and Activity Impairment: Specific Health Problem tool (Fig. 1) . (30, (33) (34) (35) (36) (37) (38) (39) (40) Although PROs have been assessed for patients with viral hepatitis and primary biliary cholangitis, PROs for NAFLD and NASH have been developed only recently. (34) Initial studies of PROs in patients with NAFLD used the SF-36 and other generic HRQL instruments. (41) These studies concluded that, compared to the general population, patients with NAFLD have reduced HRQL scores, especially in the areas of physical function. (32, 41) Furthermore, compared with scores from patients with hepatitis C virus (HCV) or hepatitis B virus (HBV) infection, patients with NAFLD scored the lowest on five of the six CLDQ domains (fatigue, activity, emotions, systemic, and worry). (35) In this study, patients with NAFLD also had the lowest HRQL scores, followed by patients with chronic HCV and HBV infection. (41) Furthermore, a diagnosis of NAFLD was an independent predictor of reduced HRQL scores. (32, 41) When assessing PROs, it is important to recognize that coexisting comorbidities affect patients' 
Work Productivity
Work Productivity Activity Impairment-Specific Health Problem (WPAI-SHP) (42) These rates are higher than the rate of depression in the general population of adults in the United States, as reported by the National Institute of Mental Health (6.7%). (43) Other important confounders that are common in patients with NAFLD and can affect HRQL scores include type 2 diabetes and obesity. (6) Although generic PRO instruments provide important data, disease-specific PRO instruments are highly desirable, due to their responsiveness and validity in patients with a specific disease. (31) An important advance in the PRO field related to liver disease has been the development of disease-specific instruments. In addition to CLDQ for patients with liver disease, there are now fully validated HRQL instruments for patients with HCV (CLDQ-HCV), primary sclerosing cholangitis, or NASH (CLDQ NAFLD-NASH). (27, (34) (35) (36) For patients with NAFLD and NASH, the recently developed and validated CLDQ NAFLD-NASH scoring system contains 36 items divided into four domains with good psychometric properties. (35, 44) CLDQ NAFLD-NASH was developed using a systematic approach with exhaustive item selection through literature search, patient interviews, focus groups and experts' input. This scoring system then underwent systematic item reduction and factor analysis and has been shown to have excellent reliability, validity and responsiveness. The methodology used for CLDQ NAFLD-NASH has been used for decades for development of disease-specific instruments and meets all the requirements of regulatory bodies for these types of internments. (30) (31) (34) (35) (36) This instrument is widely available and is being used in large international real world studies of NAFLD as well as clinical trials of NASH and should provide valuable information about PROs in these patients and their treatment strategies. (45) 
Economic Outcomes Assessments
The third pillar of the value proposition is the cost outcome-this is assessed by tracking all costs required to deliver clinical and quality outcomes to an individual, to a cohort of patients with a specific diagnosis, or to society. (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) For assessing the economic burden of a disease, different types of models are commonly used: health economic models, cost-effectiveness models, and budget impact models. Each type of analysis is used to answer a certain type of economic question. These models are based on mathematical frameworks that are designed to estimate the effects of an intervention on valued health consequences and their associated costs based on data from different sources (clinical trials, observational studies, insurance claim databases, case registries, public health statistics, and quality-of-life surveys). (46) The economic models most commonly used in health care are cost-effectiveness and budget impact models.
Cost-effectiveness models assess the overall clinical and economic outcome of a therapy in relation to interventions in the same class or different health care interventions. These models usually evaluate the effects of therapy or an intervention on patients' mortality and/or morbidity, along with their associated costs. In general, cost-effectiveness models include the use of decision tree and Markov models using a process that simulates disease progression. (46) (47) (48) In most cases, the outcomes of these models (such as years of life gained) are adjusted for their quality-of-life scores to obtain quality-adjusted life years (QALYs). (48) Budget impact models estimate the impact of an intervention on drug costs, health care cost offsets, and adverse event costs, as well as the expected use in the health care system. These models are commonly used by managed care payers because results are reported as projected cost per member per month. (47) This type of analysis is important from the budgetary standpoint but does not provide the complete picture of costs and outcomes of a specific intervention. Therefore, the most complete type of economic analysis, from a value perspective, is cost-effectiveness or cost-utility analysis, which considers cost and outcomes in a standardized manner.
An important aspect of cost-effectiveness analysis is the use of utilities to adjust clinical outcomes. The common unit of cost-effectiveness analysis is QALYs-years of life are adjusted by the quality of these years of lives gained. (48, 49) This utility assessment can be derived by different methods, but the use of utility assessments is a common approach. (50) This approach allows appropriate comparison of two or multiple interventions-the incremental cost effectiveness ratio (ICER) between two treatment groups can be determined as dollars per QALY gained. The threshold for ICER is based on willingness to pay (WTP), which is controversial and historically set at $50,000 per QALY for the United States. (48) This value is outdated and requires revision. (51) Additionally, the WTP threshold depends on the economic state of different countries. The World Health Organization has proposed connecting WTP threshold to the gross domestic product of a specific country. (49) Despite some initial suggestions of considering WTP as 3-5 times the GDP of each country, this method has a number of limitations and remains controversial. (49) The economic burden of NAFLD and NASH has only been recently assessed, using different methodologies, and is projected to be immense. (5) (6) One study modeled the projected burden of NAFLD in the United States and four European countries (Germany, France, Italy, and United Kingdom) using five steadystate prevalence models and allowing patients to transition between nine health states (NAFLD, NASH, NASH-fibrosis, NASH-compensated cirrhosis, NASH-decompensated cirrhosis, HCC, liver transplantation, post-liver transplant, and death). The modeled prevalence of NAFLD in the United States was estimated to be more than 64 million people, with annual direct medical costs of about $103 billion ($1,613 per patient). In the four European countries modeled, approximately 52 million people have NAFLD, with an annual cost of about €35 billion (from €354 to €1,163 per patient). Costs, prevalence, and incident rates were found to be highest in patients 45-65 years old. (52) In a separate Markov model focusing on NASH and advanced NASH in the United States, investigators determined that in 2017 there were 5,527,812 adult subjects with NASH (18-79 years old) in the United States. The lifetime cost burden of all NASH patients in the United States was estimated to be enormous and expected to increase by approximately 400% in the next 5 years. (53) Both economic analyses only considered the direct costs of NAFLD or NASH. The indirect costs associated with decreasing HRQL scores or work productivity associated with NASH can add to the economic burden. In fact, assessments of HRQL or health utilities, and monetization of these values, can help us estimate the indirect economic effects of NASH on society. In this context, the first step is to assess HRQL or health utilities that are associated with each stage of NASH and then monetize these utilities using the WTP threshold. (54) A recent study assessed health utilities of patients with NAFLD and compared them with those of the general population. As expected, patients with NAFLD, especially those with cirrhosis, have significant impairment, determined by lower utility scores. (32) These utility scores could be used in economic analyses to utility-adjust outcomes of patients with NAFLD and NASH. It is important to recognize the potential flaws of modeling the disease burden or the economic burden of NASH. The computerized modeling requires accurate data related to the prevalence, incidence, transition rates, cost data and utility scores. If these data are not available or the assumptions are incorrect, the model outputs could be quite inaccurate. It is also important to consider the complexity of NAFLD/NASH as a liver disease and the heterogeneity of the health care system across the world requiring country-specific data and models. In this context, it will be important to develop models for each country and each region of the world.
In addition to decision analytic Markov models, studies use the Medicare database to estimate resource use related to different liver diseases. These types of data will provide an overall assessment of the resource use and its change over time. For patients with NAFLD, investigators have reported that the mean yearly inflation-adjusted outpatient charges for Medicare patients with NAFLD doubled from $2,624-$3,308 in 2005 to $3,608-$5,132 in 2010. (55) A follow-up study, which included both the outpatient and inpatient Medicare databases, confirmed the enormous impact of NAFLD, reporting that the median total hospital charge for patients with NAFLD was $36,289 in 2010 and that this number increased with disease severity. (55) (56) More recently, using a large dataset from OptumLabs Data Warehouse, authors have reported that the total annual cost of care per NAFLD patient with private insurance was $7,804 for a new diagnosis and $3,789 for long-term management. Additionally, these costs were higher than matched controls. In fact, the largest increases in the healthcare utilization for NAFLD were related to liver biopsies, imaging and hospitalizations. (64) There are few data on the economic burden of NAFLD, but with the projected significant increase in the number of patients with NASH and associated costs, more studies are needed to identify all costs associated with NASH. These costs should include those related to loss of work productivity and the increased burden on the health care system-especially for older patients who already carry a higher comorbidity burden and cost. Further studies are needed to evaluate the cost associated with screening programs to identify patients at high risk for NAFLD and prevention methods aimed to reverse the trend of increasing NAFLD cases. (3) 
ValUe-BaSeD CaRe
Value-based care involves the focused delivery of health care to a specific group of patients, prioritizing value, rather than the volume, of care. (57) Value is proportional to clinical and quality outcomes and inversely associates with cost of delivering these outcomes. In the traditional fee for service-based health care delivery system, volume of care delivered has been emphasized rather than the value of care delivered. (57) Recently, the paradigm of delivering health care in the United States and other advanced economies has increasingly shifted from fee-for-service reimbursement to a model that is based on the value proposition. (57) Value-based care is supposedly based on what is best for society. However, maximizing value to the society can also bring the highest value to the patient. (58) It is therefore imperative that health care providers aid in determining the best measures of clinical and other patient-associated outcomes.
ValUe-BaSeD CaRe FoR NaFlD
Value-based health care is a relatively new concept in liver disease-these concepts have not been widely applied to patients with NAFLD. However, given the potentially tremendous clinical and economic burden of NAFLD and NASH, it is important to fully understand the effects of NASH on society and the economic impact of future treatments for NASH in the framework of value-based care.
Although NAFLD is common, the major focus of clinical care should be to identify patients at the highest risk for complications of advanced liver disease, which is a challenge due to suboptimal diagnostic modalities. (51, 52) Screening the general population for NASH cannot be justified based on lack of a fully validated noninvasive test. (61) On the other hand, aggressive lifestyle modifications that target components of metabolic syndrome could be beneficial. Patients with NASH at greatest risk for death can be identified based on the presence of metabolic conditions such as type 2 diabetes (62) and significant fibrosis. (16, 53) Patients with significant fibrosis also have larger reductions in quality of life. (45) NAFLD produces a significant economic burden that worsens as liver disease advances. (5, 6, 54) We must therefore develop a targeted approach to identify patients with NASH who are at greatest risk for adverse clinical outcomes. (55) To implement value-based care to NAFLD, it is important that comprehensive outcomes (clinical, PRO, and economic) are measured, to assess the total impact of NASH on individuals and society. As new treatment regimens for NASH are developed, their effects on these outcomes must be demonstrated. The first important hurdle in clinical development of therapeutic agents for NASH is to improve patient outcomes. (24) Although mortality is the ultimate clinical outcome, it is not a practical endpoint for clinical trials. (24) Improvement of fibrosis and possibly NASH can be assessed to determine efficacy. (53) Clinical trials of therapeutic agents must include PROs, and these agents must be found to improve quality outcomes, such as quality of life. (24, 56) In the final step of this comprehensive approach, an economic analysis must show that the new treatment is cost-effective, from a longterm societal perspective. (24, 55) In approaching NASH and its treatment in this manner, we will deliver the best value to patients and society.
Conclusion
Several measures are available to health care workers that can help determine the value of care. It is important to assess comprehensive outcomes (clinical, patient-reported, and economic) and how they are affected by NAFLD at its different stages. As we develop new treatment strategies for NASH, it will be important to include not only assessments of clinical outcomes but also PROs and economic outcomes. Using this comprehensive approach, we can deliver the best value to the patients and society. In this context, our ultimate goal should be to deliver value-based patient centered care for patients with NASH. This type of care will assure the best clinical outcomes and quality outcomes to our patients at the optimal costs and value to society. 
